Xcellerex’s FlexFactory being used for Humacyte candidate
Xcellerex is using its single use bioreactor system, FlexFactory, to develop a novel manufacturing process for Humacyte’s regenerative medicine candidate.
Developing a manufacturing process is the basis of an initial strategic collaboration that the companies have entered into. Xcellerex will receive manufacturing fees in exchange for providing development expertise and candidate production.
Humacyte was manufacturing the product, a vascular graft, one at a time in small-scale bioreactors. If the collaboration continues, and trials are successful, FlexFactory should allow Humacyte to scale up production through clinical development and into commercial release.
The companies have been performing collaborative design work for several months. Financial details of the deal have not been disclosed.
